Annovis Bio Inc (ANVS)
8.29
+0.26
(+3.24%)
USD |
NYSE |
May 17, 16:00
8.30
+0.01
(+0.12%)
After-Hours: 20:00
Annovis Bio Cash from Operations (Quarterly): -7.033M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -7.033M |
| December 31, 2023 | -9.365M |
| September 30, 2023 | -9.370M |
| June 30, 2023 | -9.606M |
| March 31, 2023 | -11.63M |
| December 31, 2022 | -3.609M |
| September 30, 2022 | -3.987M |
| June 30, 2022 | -6.695M |
| March 31, 2022 | -3.022M |
| December 31, 2021 | -1.769M |
| September 30, 2021 | -1.743M |
| June 30, 2021 | -3.145M |
| March 31, 2021 | -2.475M |
| Date | Value |
|---|---|
| December 31, 2020 | -0.7659M |
| September 30, 2020 | -0.9227M |
| June 30, 2020 | -1.312M |
| March 31, 2020 | -0.9704M |
| December 31, 2019 | -0.0525M |
| September 30, 2019 | -0.0447M |
| June 30, 2019 | -0.1506M |
| March 31, 2019 | -0.2287M |
| December 31, 2018 | -0.0762M |
| September 30, 2018 | -0.1288M |
| June 30, 2018 | -0.1967M |
| March 31, 2018 | -0.1569M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-11.63M
Minimum
Mar 2023
-0.0447M
Maximum
Sep 2019
-3.883M
Average
-2.748M
Median
Cash from Operations (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 18.27M |
| Ligand Pharmaceuticals Inc | 18.73M |
| FibroGen Inc | -59.29M |
| SINTX Technologies Inc | -2.733M |
| Stereotaxis Inc | -2.346M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 4.415M |
| Free Cash Flow | -35.37M |
| Free Cash Flow Per Share (Quarterly) | -0.6497 |
| Free Cash Flow Yield | -43.98% |